CVS Health plans to split into two public companies, separating about 9,000 pharmacies from Aetna and Caremark, targeting the first half of 2028. This delayed November 4 edition also covers AbbVie's IBD license for Nxera's gut-targeted NXE0033744: $100 million upfront, up to $1.37 billion in milestones, and no IBD efficacy results in the announcement. In the roundup: FDA priority review for BeOne's Brukinsa (zanubrutinib) plus rituximab in first-line mantle cell lymphoma, and Pfizer's November 3 snapshot of discontinued obesity, PAH and KRAS programs. Plus Novo Nordisk's diverging Q3 operating profit measures and FDA Breakthrough Therapy designation for Idorsia's daridorexant in pediatric insomnia.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →